Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$237.43 USD

237.43
1,209,653

+1.79 (0.76%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $237.58 +0.15 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.

Indrajit Bandyopadhyay headshot

Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More

by Indrajit Bandyopadhyay

Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.

QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down

by Zacks Equity Research

In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.

Cencora (COR) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Maharathi Basu headshot

5 Broker-Loved Stocks to Watch in an Uncertain Scenario

by Maharathi Basu

We believe that investors should keep a close watch on stocks like The Greenbrier Companies (GBX), AMC Entertainment (AMC), The Gap (GPS), Asbury Automotive (ABG) and Cencora (COR).

Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise

by Zacks Equity Research

Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.

ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) third-quarter 2023 results are likely to reflect solid underlying base business organic sales growth.

Is Cencora (COR) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why Cencora (COR) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora (COR) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Cencora (COR) Stock for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Why AmerisourceBergen (COR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why AmerisourceBergen (COR) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Implied Volatility Surging for Cencora (COR) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.

American Tower (AMT) Announces Deal to Buy CoreSite for $10.1B

by Zacks Equity Research

American Tower's (AMT) agreement to acquire CoreSite will enhance the company's portfolio and growth prospects.

What's in the Offing for Iron Mountain's (IRM) Q3 Earnings?

by Zacks Equity Research

Iron Mountain's (IRM) gains from strength in core storage and record management businesses as well as high demand for data centers are likely to have aided Q3 earnings.

What's in Store for Equinix (EQIX) This Earnings Season?

by Zacks Equity Research

Equinix's (EQIX) global data-center footprint and high demand are likely to have aided Q3 earnings, though aggressive pricing pressure might have been a deterrent.

CoreSite Realty (COR) Beats Q3 FFO Estimates

by Zacks Equity Research

CoreSite (COR) delivered FFO and revenue surprises of 1.46% and -0.97%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vornado (VNO) to Post Q3 Earnings: What's in the Offing?

by Zacks Equity Research

While Vornado's (VNO) Q3 performance is likely to have gained from the improvement in the office market, stiff competition might have been a deterrent.